Business

Commercial launch of low priced COVID-19 test approved by DGCI

The Drugs Controller General of India has approved the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) has said.

migrator

New Delhi

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement. The test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use. CRISPR is a genome editing technology to diagnose diseases. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology). 

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

VCK sees no deadlock in seat-sharing talks, says Thirumavalavan

Several trains on Salem-Jolarpettai route cancelled, diverted; check details

BJP releases list of nine candidates for Puducherry Assembly polls

Officials say at least 10 people were killed in a South Korean factory fire

Ramzan special: Muslims gather at Chennai's Don Bosco School for Eid Al-Fitr namaz